# Novartis Says AI Could Cut Drug Development From 12 Years to Eight

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/62125
Published: 2026-11-20T14:43:23.000Z
Updated: 2026-11-20T14:43:23.000Z
Section: Business

> CEO Vasant Narasimhan said AI is speeding candidate discovery and clinical operations. Novartis is targeting a higher success rate for drugs entering human testing.

Novartis CEO Vasant Narasimhan said artificial intelligence could shorten drug development from about 12 years to eight, as the Swiss drugmaker applies AI to candidate discovery, clinical trials and data analysis.

Narasimhan said AI is helping Novartis run trials faster and identify potential drug candidates. The company is targeting an increase in the probability that a drug entering human testing succeeds from 8% to 12%.

AI-assisted generative chemistry has reduced the time from starting a research program to selecting a candidate from three to four years to about 18 to 24 months. Novartis’ AI platforms can also run thousands of trial enrollment simulations in minutes, a process that previously took weeks.

By late 2026, about 90% of Novartis’ development content was AI-assisted. Clinical study report timelines were reduced by 25%, while statistical programming for 2026 trials was 90% faster.

These operational gains do not establish that drugs will pass late-stage trials or regulatory review sooner. The eight-year development timeline is a target, and 12% is Novartis’ target success rate for drugs entering human testing.


